Related Experiment Videos
Prevalence and Characteristics of North American Indigenous Inflammatory Skin Disease: A Systematic Scoping Review
Rachel Asiniwasis1, Jordanna Roesler2, Amira Muftah3
1Division of Dermatology, University of Saskatchewan, Regina, Saskatchewan, Canada.
Abstract:
Chronic inflammatory skin diseases (CISD) including atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa (HS) are chronic conditions contributing to health inequities. Their burden among North American Indigenous peoples remains poorly characterized. This scoping review assessed Indigenous representation in clinical research, Phase III/IV trials, and practice guidelines on CISD in Canada and the United States, identifying evidence gaps and proposing strategies to enhance inclusion. Following PRISMA-ScR methodology, MEDLINE, Embase, CINAHL, Cochrane Library, Indigenous-focused databases, and gray literature were searched from inception to May 2022. Phase III/IV therapeutic trials for AD and psoriasis (2011-2021) were reviewed separately to evaluate reporting of Indigenous participants and North American guidelines were screened for Indigenous considerations. Of 49 studies included, 39% specifically focused on Indigenous populations of primarily pediatric, rural, and remote Canadian cohorts. Prevalence estimates for AD among Indigenous children ranged from 10% to 25%, with frequent comorbid asthma. Data on psoriasis suggested potentially higher morbidity among First Nations populations, while HS evidence was extremely limited. Indigenous representation was minimal in clinical trials (1.3% of total participants reported under Indigenous categories across included Phase III/IV therapeutic trial reports for AD and psoriasis), and only one recent guideline explicitly incorporated Indigenous perspectives. Overall certainty in burden estimates was low, especially for psoriasis and HS. To address these gaps, key recommendations include consistent reporting of Indigenous identity, setting recruitment targets in trials, supporting Indigenous-led cohorts and registries, and integrating Indigenous and remote care expertise into guidelines. Advancing CISD research and clinical equity requires alignment with Indigenous data sovereignty and governance principles.
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease III: Crohn's Disease
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease I: Introduction